Pharmacological Study
Evaluation of subchronic genotoxic potential of Swarna Makshika Bhasma

Pavan B. Savalgi, Biswajyoti Patgiri, Jalaram H. Thakkar, B. Ravishankar, Varun B. Gupta

Reader, Department of Rasa Shastra and Bhaishajya Kalpana, Ashwini Ayurvedic Medical College and Research Centre, Tumkur, Karnataka, 1Associate Professor, Department of Rasa Shastra and Bhaishajya Kalpana including Drug Research, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, 1Lecturer, Department of Pharmacology, SSR College of Pharmacy, Silvassa, UT of D and NH, 2Director, Research and Development, SDM College of Ayurveda, Kuthpady, Udupi, Karnataka, 3PhD Scholar, Pharmacology Laboratory, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India

Abstract

Extremely diminutive published information is available on the mutagenic activity of Ayurvedic Bhasmas. Genotoxicity of few Bhasmas were reported on single maximum dose, but no reference is available on the sub-chronic level. Hence the present study was carried to generate and evaluate genotoxic potentials of Swarna Makshika Bhasma (mineral preparation) administered at therapeutic dose for 14 days. Chromosomal aberrations and abnormal sperm assay parameters were taken in this study. Cyclophosphamide (CP) was taken as positive group and results were compared. The results revealed a lack of generation of structural deformity in above parameters by tested drugs compared to CP treated group. Observed data indicate that the Bhasmas tested were non-genotoxic under the experimental conditions.

Key words: Abnormal sperm assay, chromosomal aberrations, cyclophosphamide, genotoxicity, Swarna Makshika Bhasma

Introduction

Ayurveda is known and carried forward as an ancient Indian heritage. It is a traditional medical system used by a majority of Indian population.[1] The drugs known as “Bhasmas” are well-known in the traditional Indian Ayurveda and these are chemically mixed oxides of one or more metals.[2] Their traditional preparation involves conversion of a pure metal into its oxide form following a typical procedure, available in the ancient literature of Ayurveda.[3] Recently, doubts have been raised about the safety of Ayurvedic preparations using Bhasma and concerns were expressed regarding the metal toxicity of traditional preparations containing Bhasmas. Ayurveda fraternity claims that these medicines, if properly prepared and administered are safe and therapeutic.[4] According to them toxicity can arise only from a metal in its free form, and that a Bhasma prepared according to the classical methods never contains a metal in free form. Despite these theories claiming Bhasmas are non-toxic, documented case reports of poisoning was noted.[5,6] Hence the current study of Swarna Makshika Bhasma (SMB) would serve as a database of baseline information for genotoxicity, since there is apparently no literature on this aspect of mineral preparations.

Materials and Methods

Test drugs

Three different samples of Swarna Makshika (SM) were collected from different mines across India. Bhasmas were prepared according to classical reference.[7] Coded as mentioned below:

1. SMB prepared from samples collected from Khetri Mine, Rajasthan (SMBKR).
2. SMB prepared from samples collected from Hatti Gold Mine, Karnataka (SMBHK).
3. SMB prepared from Malharjkhand Mine, Madhya Pradesh (SMBMM).

Chemicals

Colchicine was obtained from Hi-media, Mumbai. Cyclophosphamide (CP) procured as Cyphos vial from Intas Pharmaceuticals, Mumbai. Potassium chloride, methanol, acetic acid, giemsa stains were obtained from Sisso Research Laboratory, Mumbai, India.

Study design

Animals

Adult Swiss albino mice (weighing 25 ± 5 g) procured from
an institutional animal house attached to SSR College of Pharmacy, Silvasa, where the study was conducted. Animals were maintained with controlled temperature (25 ± 2°C), relative humidity of 50 ± 10% and 12 h light/dark photo-period. The animals were acclimatized for 7 days prior to the experiment and provided with standard mice feed and distilled water ad libitum. Study was carried out after obtaining approval from Institutional Animal Ethics Committee (IAEC/2011/01).

Animals were randomly divided into five groups (5 mice per group) after an acclimatization period. Group I served as positive control and challenged with CP single-dose of 25 mg/kg body weight intra-peritoneally 24 h prior to termination. Group II served as vehicle control. Vehicle was prepared in combination of honey and deionized water (with a ratio of 1:1.5) and administered in the dose of 0.5 ml/kg body weight as per CCRAS/NIN guidelines. Group III, IV, and V received SMBKR, SMBHK and SMBMM at therapeutic dose 4.5 mg/kg body weight respectively along with vehicle for 14 consecutive days and sacrificed on the 15th day. The doses of test drugs were calculated as per the reference of Paget and Barnes (1969).

**Body weight**

Animals were examined throughout the experimental period for signs of gross toxicity. Body weight was recorded initially and at the time of sacrificed on the 15th day.

**Experimental procedure**

**Chromosomal aberration assay**

Animals were injected colchicine intra-peritoneally at the dose of 4 mg/kg body weight, on the 15th day in order to arrest dividing cells in metaphase and sacrificed by cervical dislocation, 90 min after the colchicine treatment. Bone marrow cells from both femurs were extracted, subjected to hypotonic shock treatment (KCl 0.075 M), for about 30 min, at room temperature and then centrifuged at 1000 rpm for 10 min. The cells were fixed 5 times using freshly prepared methanol-acetic acid (3:1). The cells were spread on clean glass slides that were dried on a hot plate at 40°C. One more drop of fixative was added on slides to see more reliable pictures of chromosomes and then the slides were air dried at room temperature and finally stained with a 5% dilution of Giemsa reagent in a phosphate buffer (pH 6.8) for 15 min. The chromosomes of 1000 cells in metaphase aberrations were analysed with a ×100 oil immersion objective, using a Trinocular Research Carl Zeiss Microscope (Germany). Metaphases with chromosomes and chromatid breaks, gaps, rings, stickiness, centric fusion, and deletion were recorded. Vehicular control group served as negative control and CP single-dose of 25 mg/kg body weight was used as the positive control.

**Sperm abnormality assay**

The method of Wyrobek and Bruce was used for investigating sperm morphology abnormality assay. The test preparations were prepared from Khetri mine, Rajasthan; SMBHK prepared from Malharjkhand mine, Madhya Pradesh; SMBMM prepared from Hati gold mine, Karnataka; SMBKR prepared from Khetri mine, Rajasthan.

| Groups | Before treatment | On 15th day | Actual % changes |
|--------|-----------------|-------------|------------------|
| VC%    | 25.60±0.018     | 30.30±0.073  | 20.92±0.219***   |
| SMBKR  | 26.00±0.089     | 30.50±0.067  | 20.13±0.65***    |
| SMBHK  | 25.80±0.017     | 30.00±0.062  | 21.28±0.32**     |
| SMBMM  | 26.80±0.011     | 29.60±0.078  | 20.16±0.66**     |

*Data: Mean±SEM; ↑: Increase; ↓: Decrease; **P<0.01; ***P<0.001 (unpaired t-test in comparison to CP group). CP: Cyclophosphamide; VC: Vehicle control; SMBKR: Swarna Makshika Bhasma prepared from Khetri mine, Rajasthan; SMBHK: Swarna Makshika Bhasma prepared from Hati gold mine, Karnataka; SMBMM: Swarna Makshika Bhasma prepared from Malharjkhand mine, Madhya Pradesh; SEM: Standard error of mean

The effect of SMBs on body weight, chromosomal aberration and sperm abnormality assay are shown in Tables 1-3.

**Discussion**

In vivo CA assay is one of the most frequently used and sensitive tests for the detection of the genotoxic profiles of drugs. The test has been recommended for routine analysis and data obtained are considered highly relevant in human context.[11,12] In the present study a 14-day sub-chronic genotoxicity of SMBs prepared by different samples are evaluated by employing in vivo CA assay and abnormal sperm assay (ASA). Although the genotoxic profile of some of Bhasmas have been evaluated in various studies,[13] till date no reports of sub-chronic genotoxicity studies on Bhasmas and SMB are available. With this view body weight of animals also recorded after 14 days of drug administration and compared with CP group [Table 1]. All treated groups exhibited significant gain in body weight in comparison to CP. Body weight loss is an indicator of marked tissue loss in the body protein degradation. Gain of body weight is indicating that test drugs are not bearing degenerative potentials.

Colchicine is effective in causing metaphase stasis in cell dividing matrix.[14] Thus used to arrest metaphase, when chromosome structure seen noticeably. It inhibits microtubule polymerization by binding to tubulin, one of the main constituents of microtubules. Availability of tubulin is essential to mitosis, and therefore, colchicine effectively functions as a “mitotic poison” or spindle poison. Hypotonic solution (KCl) causes the cells to swell and enhances eventual separation of the chromosomes to facilitate visual analysis.

### Table 1: Effect of SMBs on body weight

| Groups   | Before treatment | On 15th day | Actual % changes |
|----------|-----------------|-------------|------------------|
| CP       | 25.20±0.086     | 27.30±0.086 | 06.58±0.029      |
| VC%      | 25.60±0.018     | 30.30±0.073 | 20.92±0.219***   |
| SMBKR    | 26.00±0.089     | 30.50±0.067 | 20.13±0.65***    |
| SMBHK    | 25.80±0.017     | 30.00±0.062 | 21.28±0.32**     |
| SMBMM    | 26.80±0.011     | 29.60±0.078 | 20.16±0.66**     |

Data: Mean±SEM; ↓ Decrease; ↑ Increase; **P<0.01; ***P<0.001 (unpaired t-test in comparison to CP group). CP: Cyclophosphamide; VC: Vehicle control; SMBKR: Swarna Makshika Bhasma prepared from Khetri mine, Rajasthan; SMBHK: Swarna Makshika Bhasma prepared from Hati gold mine, Karnataka; SMBMM: Swarna Makshika Bhasma prepared from Malharjkhand mine, Madhya Pradesh; SEM: Standard error of mean
CP is an anticancer drug that is widely used in anti-neoplastic therapy as well as in the treatment of some non-malignant diseases like rheumatoid arthritis. It is also used as an immunosuppressive agent prior to organ transplantation. In somatic cells, CP has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation. The compound also produced chromosome damage and micronuclei in rats, mice and Chinese hamster. Its use as a positive control chemical in genotoxicity tests has been recommended. It increased the number of chromosome aberrations in the given dose with relatively high frequencies of chromosome breaks, centric fusion compared with other types of chromosome abnormalities. Gap, ring formation as well as stickiness were also frequent in CP treated group [Figure 1a-f]. This may be
because almost all mouse chromosomes are acrocentric. These types of chromosomes have the exceptional facility to merge with each other. Only structural aberrations were enumerated in all treated groups [Figure 1g-j] against CP treated group, with special emphasis on chromosome and chromatid gap, breaks and centric diffusions placed in Table 2.

Table 2: Effect of SMBs on chromosomal aberration

| Groups   | Chromatid Gap Break | Chromosomal De Ex Fg | PS | R | Dc |
|----------|---------------------|-----------------------|----|---|----|
| CP       | +                   | +                     | +  | + | +  |
| VC       | -                   | -                     | -  | - | -  |
| SMBKR    | --                  | --                    | -  | - | -  |
| SMBHK    | --                  | --                    | -  | - | -  |
| SMBMM    | --                  | --                    | -  | - | -  |

+: Presence; - Absence; De: Deletion; Ex: Exchange; Fg: Fragmentation; PS: Pulverization and stickiness; R: Ring; Dc: Dicentric; CP: Cyclophosphamide; VC: Vehicle control; SMBKR: Bhasma prepared from Swarna Makshika collected from Khetri mine, Rajasthan; SMBHK: Bhasma prepared from Swarna Makshika collected from Hatti gold mine, Karnataka; SMBMM: Bhasma prepared from Swarna Makshika collected from Malharjkhand mine, Madhya Pradesh; SEM: Standard error of mean
Morphological abnormalities of sperms are described as two types as head and tail abnormalities. The head abnormality included amorphous shape, without hook, banana shaped and folded head. CP treated group observed maximum number of abnormalities in both head and tail as shown in Table 3. Amorphous shaped head, hook less head and coiled-tailed abnormalities were more frequent than other abnormalities of head and tail of CP treated group [Figures 2a-d]. The test preparations observed negative results in sperm abnormality showing non-toxic to sperms [Figures 2e-h]. Wyrobek[10] reported that large reductions in sperm number or mortality or large increases in sperm with abnormal shapes are associated with reduced fertility.

Conclusion

Present study revealed that SMB prepared from different samples were found to be safe after the administration for 14 days at the therapeutic doses. No abnormality was noticed in CA and sperm abnormal aberrations in all trial groups. Further, above findings provide new information that may be more imperative for the use of Bhasmas.

Acknowledgment

Authors acknowledge to Chairman/Principle, SSR College of Pharmacy for his kind permission for the experimental study. Authors are also indebted to Director, Prof. M.S. Baghel, I.P.G.T. and R.A., G.A.U., Jamnagar, for financial support for the project. The authors are thankful to Prof. P. K. Prajapati, Head, and Dr. Galib, Asst. Prof., Dept of R.S. and B.K., I.P.G.T. and R.A., G.A.U., Jamnagar, for their valuable help.

References

1. Gogtay NJ, Bhatt HA, Dalvi SS, Kshirsagar NA. The use and safety of non-allopathic Indian medicines. Drug Saf 2002;25:1005-19.
2. Wadakar MP, Rode CV, Bendale VN, Patil KR, Prabhune AA. Preparation and characterization of a copper based Indian traditional drug Tamra bhasma. J Pharm Biomed Anal 2005;39:951-5.
3. Kulkarni-Dudhgaonkar SB. In: Rasaratna Samuchyaya of Vagbhatta. Kolhapur, India: Shiviha University Publication 1970. p. 158.
4. Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 2002;57:891-6.
5. Araujo J, Beelen A, Lewis LD, Robinson GG, DeLaurier C, Barbajaj M, et al. Centres for Disease Control and Prevention. Lead poisoning associated with use of Ayurvedic Medications – five states, 2000-2003. MMWR Morb Mortal Wkly Rep 2004;53:582-4.
6. Buwa S, Patel S, Kulkarni PH, Kanase A. Hepatoprotective action of abhrak bhasma, an ayurvedic drug in albino rats against hepatitis induced by CCl4. Indian J Exp Biol 2001;39:1022-7.
7. Vagbhata, Rasaratna Samuchaya. In: Kulkarni DA, editor. 3rd ed., verse 2/78-80. New Delhi: Meherchandra Laxshandas Publication; 1987. p. 28.
8. Mueller GA, Gaulden ME, Drane W. The effects of varying concentrations of colchicine on the progression of grasshopper neuroblasts into metaphase. J Cell Biol 1971;48:253-65.
9. Tjo JH, Whang J. Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration. Stain Technol 1962;37:17-20.
10. Wyrobek AJ, Bruce WR. The induction of sperm shape abnormalities in mice and humans. In: Hallender A, de Serres FJ, editors. Chemical Mutagens. Vol. 5: New York; Plenum Press 1975. p. 275-85.
11. Anonymous. International commission for protection against environmental mutagen and carcinogens report of committee. Mutat Res 1983;114:120-77.
12. World Health Organization. Guidelines to short-term tests for detecting mutagenic and carcinogenic chemicals. Environmental Health Criteria 51. Geneva:WHO; 1985. p. 100-14.
13. Vardhini NV, Sathyen TN, Murthy PB. Assessment of genotoxic potential of herbo-mineral preparations – Bhasmas (Research communications). Curr Sci 2010;99:1096-100.
14. Fraser IEB. The use of colchicine and colcemid for metaphase stais in the matrix cells of wool follicles. Aust J Biol Sci 1962;16:211-17.
15. Jackson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutat Res 1996;355:171-208.
16. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 1995;330:115-35.
17. Krishna G, Petreche J, Anderson J, Theiss J. Use of cyclophosphamide as a positive control in dominant lethal and micronuclear assays. Mutat Res 1995;330:115-81.
18. Wyrobek AJ, Gordon LA, Burk hart JG, Francis MW, Kapp RW Jr, Letz G. An evaluation of the mouse sperm morphology test and other sperm tests in non-human mammals: A report of the US Environmental Protection Agency Gene Toxicology Program. Mutat Res 1983;115:1-72.